Hermine I Brunner1, Michael R Bennett1, Khalid Abulaban1, Marisa S Klein-Gitelman2, Kathleen M O'Neil3, Lori Tucker4, Stacy P Ardoin5, Kelly A Rouster-Stevens6, Karen B Onel7, Nora G Singer8, B Anne Eberhard9, Lawrence K Jung10, Lisa Imundo11, Tracey B Wright12, David Witte1, Brad H Rovin5, Jun Ying13, Prasad Devarajan1. 1. Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, Ohio. 2. Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University, Chicago, Illinois. 3. Riley Hospital for Children at IU Health, Indiana University School of Medicine, Indianapolis. 4. British Columbia Children's Hospital, Vancouver, British Columbia, Canada. 5. Ohio State University Wexner Medical Center, Columbus. 6. Emory University School of Medicine, Atlanta, Georgia. 7. Comer Children's Hospital, University of Chicago School of Medicine, Chicago, Illinois. 8. Rainbow Babies and Children's Hospital/Case Medical Center and MetroHealth Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio. 9. Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park. 10. Children's National Medical Center, Washington, DC. 11. Columbia University Medical Center, New York, New York. 12. University of Texas Southwestern Medical Center, Dallas. 13. University of Cincinnati, Cincinnati, Ohio.
Abstract
OBJECTIVE: Noninvasive estimation of the degree of inflammation seen on kidney biopsy with lupus nephritis (LN) remains difficult. The objective of this study was to develop a Renal Activity Index for Lupus (RAIL) that, based solely on laboratory measures, accurately reflects histologic LN activity. METHODS: We assayed traditional LN laboratory tests and 16 urine biomarkers (UBMs) in children (n = 47) at the time of kidney biopsy. Histologic LN activity was measured by the National Institutes of Health activity index (NIH-AI) and the tubulointerstitial activity index (TIAI). High LN-activity status (versus moderate/low) was defined as NIH-AI scores >10 (versus ≤10) or TIAI scores >5 (versus ≤5). RAIL algorithms that predicted LN-activity status for both NIH-AI and TIAI were derived by stepwise multivariate logistic regression, considering traditional biomarkers and UBMs as candidate components. The accuracy of the RAIL for discriminating by LN-activity status was determined. RESULTS: The differential excretion of 6 UBMs (neutrophil gelatinase-associated lipocalin, monocyte chemotactic protein 1, ceruloplasmin, adiponectin, hemopexin, and kidney injury molecule 1) standardized by urine creatinine was considered in the RAIL. These UBMs predicted LN-activity (NIH-AI) status with >92% accuracy and LN-activity (TIAI) status with >80% accuracy. RAIL accuracy was minimally influenced by concomitant LN damage. Accuracies between 71% and 85% were achieved without standardization of the UBMs. The strength of these UBMs to reflect LN-activity status was confirmed by principal component and linear discriminant analyses. CONCLUSION: The RAIL is a robust and highly accurate noninvasive measure of LN activity. The measurement properties of the RAIL, which reflect the degree of inflammatory changes as seen on kidney biopsy, will require independent validation.
OBJECTIVE: Noninvasive estimation of the degree of inflammation seen on kidney biopsy with lupus nephritis (LN) remains difficult. The objective of this study was to develop a Renal Activity Index for Lupus (RAIL) that, based solely on laboratory measures, accurately reflects histologic LN activity. METHODS: We assayed traditional LN laboratory tests and 16 urine biomarkers (UBMs) in children (n = 47) at the time of kidney biopsy. Histologic LN activity was measured by the National Institutes of Health activity index (NIH-AI) and the tubulointerstitial activity index (TIAI). High LN-activity status (versus moderate/low) was defined as NIH-AI scores >10 (versus ≤10) or TIAI scores >5 (versus ≤5). RAIL algorithms that predicted LN-activity status for both NIH-AI and TIAI were derived by stepwise multivariate logistic regression, considering traditional biomarkers and UBMs as candidate components. The accuracy of the RAIL for discriminating by LN-activity status was determined. RESULTS: The differential excretion of 6 UBMs (neutrophil gelatinase-associated lipocalin, monocyte chemotactic protein 1, ceruloplasmin, adiponectin, hemopexin, and kidney injury molecule 1) standardized by urine creatinine was considered in the RAIL. These UBMs predicted LN-activity (NIH-AI) status with >92% accuracy and LN-activity (TIAI) status with >80% accuracy. RAIL accuracy was minimally influenced by concomitant LN damage. Accuracies between 71% and 85% were achieved without standardization of the UBMs. The strength of these UBMs to reflect LN-activity status was confirmed by principal component and linear discriminant analyses. CONCLUSION: The RAIL is a robust and highly accurate noninvasive measure of LN activity. The measurement properties of the RAIL, which reflect the degree of inflammatory changes as seen on kidney biopsy, will require independent validation.
Authors: Brad H Rovin; Huijuan Song; Lee A Hebert; Tibor Nadasdy; Gyongyi Nadasdy; Daniel J Birmingham; Chack Yung Yu; Haikady N Nagaraja Journal: Kidney Int Date: 2005-10 Impact factor: 10.612
Authors: Brad H Rovin; Huijuan Song; Dan J Birmingham; Lee A Hebert; Chack Yung Yu; Haikady N Nagaraja Journal: J Am Soc Nephrol Date: 2004-12-15 Impact factor: 10.121
Authors: Sanju A Varghese; T Brian Powell; Milos N Budisavljevic; Jim C Oates; John R Raymond; Jonas S Almeida; John M Arthur Journal: J Am Soc Nephrol Date: 2007-02-14 Impact factor: 10.121
Authors: Hermine I Brunner; Michael R Bennett; Rina Mina; Michiko Suzuki; Michelle Petri; Adnan N Kiani; Joshua Pendl; David Witte; Jun Ying; Brad H Rovin; Prasad Devarajan Journal: Arthritis Rheum Date: 2012-08
Authors: Michael Bennett; Catherine L Dent; Qing Ma; Sudha Dastrala; Frank Grenier; Ryan Workman; Hina Syed; Salman Ali; Jonathan Barasch; Prasad Devarajan Journal: Clin J Am Soc Nephrol Date: 2008-03-12 Impact factor: 8.237
Authors: N Hiramatsu; T Kuroiwa; H Ikeuchi; A Maeshima; Y Kaneko; K Hiromura; K Ueki; Y Nojima Journal: Rheumatology (Oxford) Date: 2008-04-04 Impact factor: 7.580
Authors: Daniel J Birmingham; Michael Merchant; Sushrut S Waikar; Haikady Nagaraja; Jon B Klein; Brad H Rovin Journal: Nephrol Dial Transplant Date: 2017-01-01 Impact factor: 5.992
Authors: Hermine I Brunner; Michael R Bennett; Gaurav Gulati; Khalid Abulaban; Marisa S Klein-Gitelman; Stacy P Ardoin; Lori B Tucker; Kelly A Rouster-Stevens; David Witte; Jun Ying; Prasad Devarajan Journal: J Rheumatol Date: 2017-06-15 Impact factor: 4.666
Authors: G Gulati; M R Bennett; K Abulaban; H Song; X Zhang; Q Ma; S V Brodsky; T Nadasdy; C Haffner; K Wiley; S P Ardoin; P Devarajan; J Ying; B H Rovin; H I Brunner Journal: Lupus Date: 2016-12-19 Impact factor: 2.911
Authors: Hermine I Brunner; Gaurav Gulati; Marisa S Klein-Gitelman; Kelly A Rouster-Stevens; Lori Tucker; Stacey P Ardoin; Karen B Onel; Rylie Mainville; Jessica Turnier; Pinar Ozge Avar Aydin; David Witte; Bin Huang; Michael R Bennett; Prasad Devarajan Journal: Pediatr Nephrol Date: 2018-08-29 Impact factor: 3.714
Authors: Jennifer C Davies; Emil Carlsson; Angela Midgley; Eve M D Smith; Ian N Bruce; Michael W Beresford; Christian M Hedrich Journal: Rheumatology (Oxford) Date: 2021-08-02 Impact factor: 7.580